Intensity Therapeutics Inc. (NASDAQ:INTS) Sees Large Drop in Short Interest

Intensity Therapeutics Inc. (NASDAQ:INTS) was the recipient of a significant drop in short interest in the month of September. As of September 15th, there was short interest totaling 31,298 shares, a drop of 36.0% from the August 31st total of 48,911 shares. Based on an average daily trading volume, of 12,048 shares, the days-to-cover ratio is presently 2.6 days. Currently, 1.0% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of brokerages recently issued reports on INTS. Citigroup reiterated a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. HC Wainwright raised their target price on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Intensity Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Intensity Therapeutics Stock Performance

Shares of NASDAQ INTS opened at $3.37 on Thursday. The company has a market cap of $10.99 million, a P/E ratio of -0.94 and a beta of 2.76. Intensity Therapeutics has a 52-week low of $3.27 and a 52-week high of $43.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. The firm’s fifty day moving average is $4.15 and its two-hundred day moving average is $4.63.

Intensity Therapeutics (NASDAQ:INTS) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). As a group, analysts anticipate that Intensity Therapeutics will post -2.64 EPS for the current fiscal year.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors and stimulate the body’s immune system. The company’s approach is based on its proprietary DfuseRx technology, which is intended to improve the delivery of anticancer agents into tumor cells while promoting an immune response against treated and potentially untreated tumors.

Its lead product candidate, INT230-6, is an investigational intratumoral therapy that combines the cancer-killing agents cisplatin and vinblastine with a formulation designed to facilitate their distribution within tumors.